












SHEET 1 OF 2

| | | | | | | | | | |
|---|---|--|-------------------------|---|---------------|----------------------|---------------------------------------|--------------------------|-----------------------------|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies; Lo; Lan; Wesolowski SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | | |
|  | A1 | 5,908,626 | June 1, 1999 | Hybrid with Interferon- and an Immunoglobulin Fc Joined by a Peptide Linker | 424- 134.1 | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG Y/N |
|  | B1 | WO 92/08495 | 29 May 1992 | PCT | | | | | |
|  | B2 | WO 95/05468 | 23 February 1995 | PCT | | | | | |
|  | B3 | WO 96/18412 | 20 June 1996 | PCT | | | | | |
|  | B4 | WO 97/00319 | 3 January 1997 | PCT | | | | | |
|  | B5 | WO 97/20062 | 5 June 1997 | PCT | | | | | |
|  | B6 | WO 97/33617 | 18 September 1997 | PCT | | | | | |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | | | | | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | | | | | | | |
|  | C1 | M. Mark, et al.: "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 36, 25 December 1992, pages 26166-26171. | | | | | | | |



7-17-02



| | | |
|--|----|--|
| 2 | C2 | S. Gillies, et al.: "Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins." BIOCONJUGATE CHEMISTRY, 1993 May-June, 4 (3) pages 230-235. |
| 2 | C3 | Xin Xiao Zheng, et al.: "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation." J. IMMUNOLOGY, 1995, 154(10), pages 5590-5600. |
| 2 | C4 | R.A. Reisfeld, et al.: "Recombinant antibody fusion proteins for cancer immunotherapy." CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1996) 213 (PT 3) pages 27-53. REF: 67. |
| 2 | C5 | E.T. Harvill, et al. "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation." JOURNAL OF IMMUNOLOGY. (1996 October 1) 157 (7) pages 3165-3170. |
| 2 | C6 | G. Lieschke, et al.: "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." NATURE BIOTECHNOLOGY, vol. 15, no. 1, January 1997, pages 35-40. |
| 2 | C7 | T. Kim, et al.: "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 9, 1 May 1997, pages 4137-4144. |
| 2 | C8 | S. Gillies, et al.: "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases." THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 12, 15 June 1998, pages 6195-6203. |
| 2 | C9 | S.D. Gillies, et al.: "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors." CANCER RESEARCH. (1999 May 1) 59 (9) pages 2159-2166. |
| | | |
| EXAMINER  | | DATE CONSIDERED 7-17-02 |

WALLER4006/13.867180-1